Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Anne Cunniffe Marcy"'
Autor:
Bita Sahaf, Sreevidya Kurra, Michelle Fujimoto, Anne Cunniffe Marcy, Crystal L. Mackall, Emily Egeler, Gerald A. Grant, Angus Toland, Kayla Landrum, John S. Tamaresis, Sneha Ramakrishna, Rebecca Richards, Paul G. Fisher, Kara L. Davis, Courtney Erickson, Steven A. Feldman, Sharon Mavroukakis, Michael Kunicki, Michelle Monje, Timothy T. Cornell, Sonia Partap, Agnes Reschke, Lindsay Rasmussen, Jasia Mahdi, Valentin Barsan, Hannes Vogel, Robbie G. Majzner, Cynthia J. Campen, Jennifer Moon, Zach Ehlinger, Christina Baggott, Kristen W. Yeom, Liora M. Schultz, Harshini Chinnasamy, Shabnum Patel, Aaron Mochizuki
Publikováno v:
Neuro-Oncology
Background We previously discovered high expression of the disialoganglioside GD2 on H3K27M+ gliomas and demonstrated preclinical efficacy of intravenous (IV) GD2-targeted chimeric antigen receptor (CAR) T-cells in preclinical models of H3K27M-mutate
Autor:
Michael Kunicki, Ozlem Equils, Michelle Fujimoto, Sneha Ramakrishna, Catherine Aftandilian, Anne Cunniffe Marcy, Crystal L. Mackall, Liora M. Schultz, Kara L. Davis, Radha Duttagupta
Publikováno v:
Transplantation and Cellular Therapy. 27:S215-S216
Autor:
Steven A. Feldman, Courtney Erickson, Sharon Mavroukakis, Kara L. Davis, Anne Cunniffe Marcy, Rebecca Richards, Emily Egeler, Zach Ehlinger, Crystal L. Mackall, Kristen W. Yeom, Angus Toland, Bita Sahaf, Agnes Reschke, Michael Kunicki, Michelle Fujimoto, Gerald A. Grant, Aaron Mochizuki, Liora M. Schultz, Harshini Chinnasamy, Shabnum Patel, John S. Tamaresis, Michelle Monje, Lindsey Rasmussen, Christina Baggott, Paul G. Fisher, Jennifer Moon, Cynthia J. Campen, Kayla Landrum, Hannes Vogel, Robbie G. Majzner, Sneha Ramakrishna, Sreevidya Kurra, Valentin Barsan, Sonia Partap, Timothy T. Cornell, Jasia Mahdi
Publikováno v:
Cancer Research. 81:CT031-CT031
Background: Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas (DMGs) are universally lethal central nervous system tumors. We previously discovered that the disialoganglioside GD2 is highly and homogenously expr
Autor:
Courtney Erickson, Sharon Mavroukakis, Lindsey Rasmussen, Emily Egeler, Rebecca Richards, Sonia Partap, John S. Tamaresis, Aaron Mochizuki, Anne Cunniffe Marcy, Kristen W. Yeom, Jennifer Moon, Harshini Chinnasamy, Steven A. Feldman, Gerald A. Grant, Zach Ehlinger, Crystal L. Mackall, Agnes Reschke, Christina Baggot, Paul G. Fisher, Liora M. Schultz, Shabnum Patel, Kayla Landrum, Zina Good, Michelle Monje, Cynthia J. Campen, Michael Kunicki, Michelle Celones, Timothy T. Cornell, Jasia Mahdi, Sreevidya Kurra, Hannes Vogel, Robbie G. Majzner, Valentin Barsan, Kara L. Davis, Bita Sahaf, Angus Toland, Sneha Ramakrishna
Publikováno v:
Neuro-Oncology
Introduction We are conducting a Phase I clinical trial utilizing chimeric antigen receptor (CAR) T-cells targeting GD2 (NCT04196413) for H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) and spinal cord diffuse midline glioma (DMG). Cerebrospina
Autor:
Anne Cunniffe Marcy, Terry J. Fry, Bita Sahaf, Kara L. Davis, Crystal L. Mackall, Juliana Craig, Michelle Fujimoto, Lori Muffly, Haiying Qin, Katherine A. Kong, Nasheed Hossain, Jay Y. Spiegel, Jenny Sumin Yoon, David B. Miklos, Robbie G. Majzner, Liora M. Schultz, Emily Egeler, Neehar Bhatia, Sneha Ramakrishna, Meena Kadapakkam, Christina Baggott, Courtney Erickson, Sharon Mavroukakis, Everett Meyer, Matthew J. Frank, Shabnum Patel, Steven A. Feldman
Publikováno v:
Blood. 134:744-744
Introduction: Chimeric antigen receptor (CAR) T cells targeting either CD19 or CD22 have yielded striking complete remission (CR) rates of 70%-90% in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), but CD19 negative and C
Autor:
Bita Sahaf, Haiying Qin, Lori Muffly, Kara L. Davis, David B. Miklos, Christie Chaudry, Stephen Kim, Everett Meyer, Katherine A. Kong, Anne Cunniffe Marcy, Crystal L. Mackall, Christina Baggott, Liora M. Schultz, Terry J. Fry, Sharon Mavroukakis
Publikováno v:
Blood. 132:898-898
Chimeric Antigen Receptor (CAR) therapy targeting CD19 achieves complete remission (CR) rates of 70%-90% in relapsed/refractory B-ALL. Relapse due to loss of the CD19 targeted epitope presents a therapeutic challenge as evidenced by the largest globa